ABT · News · 20260819N
Revenue Performance and Mix
ABBOTT LABORATORIES · 2026-08-19 · Importance 31 · Surprise 32 · In source text
Abbott reported 4.8% year-over-year sales growth in the second quarter of 2026, with revenue reaching $12.59 billion. Growth was driven by Nutrition, Diagnostics—including cancer diagnostics—and Medical Devices, with the Exact Sciences acquisition contributing to the portfolio mix. The results exceeded analyst expectations and reflected broad-based performance across Abbott’s major businesses.
Key facts
- Q2 2026 reported revenue: $12.59 billion and diluted EPS: $1.31. source
- Q2 2026 sales growth: 4.8% year-over-year. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | unclear | realized | — | Q2 2026 reported revenue: $12.59 billion and diluted EPS: $1.31. |
| net_income | unclear | realized | — | Q2 2026 reported revenue: $12.59 billion and diluted EPS: $1.31. |